Switch theme
Sign up to access all valuation multiples
Daan Gene Co Ltd is a high-tech enterprise-oriented in molecular diagnostic techniques. It is primarily committed to research and development, production, and service of in-vitro diagnostic products, including qPCR, Sequeacing, TRF, ELISA, and Liquid-Based Cytology diagnostic kits and equipment. Geographically, tahe group operates in China.
1988
512
Last FY Revenue $118M
Last FY EBITDA -$98.7M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Daan Gene achieved revenue of $118M and an EBITDA of -$98.7M.
Daan Gene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Daan Gene valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $118M | XXX | XXX | XXX |
| Gross Profit | XXX | $44.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 38% | XXX | XXX | XXX |
| EBITDA | XXX | -$98.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -83% | XXX | XXX | XXX |
| EBIT | XXX | -$31.8M | XXX | XXX | XXX |
| EBIT Margin | XXX | -27% | XXX | XXX | XXX |
| Net Profit | XXX | -$128M | XXX | XXX | XXX |
| Net Margin | XXX | -108% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Daan Gene's stock price is CNY 6 (or $1).
Daan Gene has current market cap of CNY 8.5B (or $1.2B), and EV of CNY 7.8B (or $1.1B).
See Daan Gene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.2B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Daan Gene has market cap of $1.2B and EV of $1.1B.
Daan Gene's trades at 9.1x EV/Revenue multiple, and -10.9x EV/EBITDA.
Equity research analysts estimate Daan Gene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Daan Gene's P/E ratio is not available.
See valuation multiples for Daan Gene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 9.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -33.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 61.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDaan Gene's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Daan Gene's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Daan Gene's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Daan Gene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -83% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daan Gene acquired XXX companies to date.
Last acquisition by Daan Gene was XXXXXXXX, XXXXX XXXXX XXXXXX . Daan Gene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Daan Gene founded? | Daan Gene was founded in 1988. |
| Where is Daan Gene headquartered? | Daan Gene is headquartered in China. |
| How many employees does Daan Gene have? | As of today, Daan Gene has 512 employees. |
| Is Daan Gene publicy listed? | Yes, Daan Gene is a public company listed on SHE. |
| What is the stock symbol of Daan Gene? | Daan Gene trades under 002030 ticker. |
| When did Daan Gene go public? | Daan Gene went public in 2004. |
| Who are competitors of Daan Gene? | Similar companies to Daan Gene include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Daan Gene? | Daan Gene's current market cap is $1.2B |
| Is Daan Gene profitable? | Yes, Daan Gene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
